Načítá se...
Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC-I antigen presentation and increased PD-L1 expression
In order to arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC-I low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main anti-tumor host defense, CD8(+) T cells. The molecular mechanisms that led to the...
Uloženo v:
| Vydáno v: | J Immunol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6761035/ https://ncbi.nlm.nih.gov/pubmed/31471524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1900475 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|